ABSTRACT Both fruquintinib and TAS‐102 monotherapies are guideline‐recommended for third‐line treatment of metastatic colorectal cancer (mCRC). This study aimed to analyze the preliminary outcomes of fruquintinib combined with TAS‐102, with or without stereotactic body radiation therapy (SBRT), as a third‐ or later‐line therapy for mCRC. This prospective, two‐arm, phase II study planned to enroll 66 patients with mCRC who were unresponsive to at least two prior lines of therapy. Patients were allocated to either the FTS (fruquintinib + TAS‐102 + SBRT) or FT (fruquintinib + TAS‐102) group. Eligible patients received fruquintinib (4 mg, qd, days 1–21) and TAS‐102 (30 mg/m2, bid, days 1–5; 15–19) orally every 4 weeks until disease progression or intolerable toxicity. The primary endpoint was progression‐free survival (PFS, per RECIST 1.1); secondary endpoints included overall survival (OS), objective response rate (ORR), disease control rate (DCR), and adverse events (AEs, graded using CTCAE v5.0). By January 20, 2025, 40 patients were enrolled (FTS group, 11; FT group, 29), with a median follow‐up of 8.48 months. In 20 (50%) patients, the number of metastatic organs was ≥ 3. However, the number of metastatic lesions was > 5 in 32 (80%) patients. For the 36 eligible patients, the ORR and DCR were 19.4% and 88.9%, respectively. The median PFS was 8.58 months; however, the median OS has not been attained. The most common treatment‐related AE was decreased white blood cell count (92.5%); grade 3–4 AEs included decreased lymphocyte count (12.5%). No treatment‐related death occurred. Fruquintinib combined with TAS‐102, with or without SBRT, showed promising preliminary efficacy and acceptable safety as third‐ or later‐line treatment of mCRC.

Background:The increasing prevalence of colorectal cancer (CRC) is a challenge for China's healthcare system. Using hospitalization data from Ningbo, China, this study aims to estimate the medical treatment cost and cost structure of CRC based on tumor sites to gain insights with respect to the cost efficiency of early diagnosis. Methods:A retrospective observational study was performed in a real-life clinical setting of a tertiary hospital in Ningbo, China. Sociodemographic, clinicopathologic, and CRC medical treatment cost data were extracted from the inpatients' medical records. The study comprised inpatients aged above 18 diagnosed with CRC and received surgical treatment between 2020 and 2022. CRC costs were separated into six cost categories and analyzed separately by tumor site (rectum and colon). All cost data were measured by 2020 Chinese Yuan. Results:A total of 538 inpatients were included, where 63.9% were male, 67.5% were diagnosed with rectal cancer, and 47.2% were at Stages III and IV. Medical treatment costs of rectal cancer increased significantly from Stage I to Stage IV in all cost categories (p < 0.001), with percentage increases ranging from 70% to 120%, depending on cost category. Medication, materials, and examinations were the major sources of CRC costs for both rectal and colon cancers, with each accounting for 20%-30% of total costs, depending on tumor site and cancer stage. Conclusions:Targeted programs for the management and treatment of various tumor sites should be considered, as rectal cancer costs are more stage-sensitive than colon cancer. The large proportion of costs attributed to medication, materials, and examinations provides guidance to the government in regulating the healthcare market to alleviate the economic burden of CRC.

This study analyzed targeted sequencing data from 6530 tissue samples from patients with metastatic Chinese colorectal cancer (CRC) to identify low mutation frequency and subgroup-specific driver genes, using three algorithms for overall CRC as well as across different clinicopathological subgroups. We analyzed 425 cancer-related genes, identifying 101 potential driver genes, including 36 novel to CRC. Notably, some genes demonstrated subgroup specificity; for instance, ERBB4 was found as a male-specific driver gene and mutations of ERBB4 only influenced the prognosis of male patients with CRC. This sex disparity of ERBB4 was validated in an independent large-scale Memorial Sloan Kettering Cancer Center CRC cohort with 2444 samples. Furthermore, using network-based stratification based on protein-protein interaction, we classified the microsatellite stable (MSS) and unstable (MSI) CRCs into six and three major subtypes, respectively, each showing unique phenotypes and prognoses. In MSS CRC, cluster 5 (APCAMER1-KRAS) and cluster 2 (RNF43-BRAF-PIK3CA) were predominant, and cluster 5 showed a superior overall survival compared with cluster 2. This extensive heterogeneity in driver gene mutations underscores the complexity of CRC and suggests significant implications for treatment and prognostic assessments.

Colorectal cancer (CRC) is the third most common cancer globally, with incidence and mortality rates projected to rise significantly by 2040. RAS mutations are prevalent in CRC and associated with poor prognosis, yet their role in early-stage CRC remains debated. Metabolomics has revealed metabolic profile differences between CRC patients and healthy individuals, as well as between RAS-mutant and wild-type CRC patients, but the specific roles and mechanisms of metabolites in these groups require further investigation. This study collected 49 CRC tissue samples, including 28 RAS-mutant and 21 wild-type samples. Liquid chromatography - mass spectrometry (LC-MS) was used for metabolite analysis, and multivariate statistical analysis, differential metabolite analysis, and pathway enrichment analysis were employed to compare the metabolic characteristics of the two groups. Multivariate statistical analysis showed relatively large within-group variation but marked differences between the RAS-mutant (M1) and wild-type (W1) groups. Differential metabolite analysis identified 70 upregulated and 134 downregulated metabolites in the M1 group. For example, omega-hydroxy myristic acid and 4 S-hydroxylauric acid were upregulated, while SCHEMBL1056153 and Immepip were downregulated. Correlation analysis revealed relationships between certain metabolites. Pathway enrichment analysis indicated that differentially expressed metabolites were mainly enriched in pathways such as Choline metabolism in cancer, Drug metabolism - cytochrome P450, and beta-Alanine metabolism at KEGG Level 3. Reactome enrichment analysis also revealed associations with specific pathways. This study reveals significant metabolic differences between RAS-mutant and wild-type CRC, identifying key differential metabolites and enriched pathways. These findings enhance the understanding of RAS-mutant CRC metabolism and provide candidate metabolites and pathways that warrant further validation as diagnostic or therapeutic targets. However, the study’s limitations, such as the relatively small sample size, should be considered, and further research is needed to explore the clinical applications and significance of these findings.

BACKGROUND:Colorectal cancer (CRC) is a serious threat worldwide. Although early screening is suggested to be the most effective method to prevent and control CRC, the current situation of early screening for CRC is still not optimistic. In China, the incidence of CRC in the Yangtze River Delta region is increasing dramatically, but few studies have been conducted. Therefore, it is necessary to develop a simple and efficient early screening model for CRC.AIM:To develop and validate an early-screening nomogram model to identify individuals at high risk of CRC.METHODS:Data of 64448 participants obtained from Ningbo Hospital, China between 2014 and 2017 were retrospectively analyzed. The cohort comprised 64448 individuals, of which, 530 were excluded due to missing or incorrect data. Of 63918, 7607 (11.9%) individuals were considered to be high risk for CRC, and 56311 (88.1%) were not. The participants were randomly allocated to a training set (44743) or validation set (19175). The discriminatory ability, predictive accuracy, and clinical utility of the model were evaluated by constructing and analyzing receiver operating characteristic (ROC) curves and calibration curves and by decision curve analysis. Finally, the model was validated internally using a bootstrap resampling technique.RESULTS:Seven variables, including demographic, lifestyle, and family history information, were examined. Multifactorial logistic regression analysis revealed that age [odds ratio (OR): 1.03, 95% confidence interval (CI): 1.02-1.03, P < 0.001], body mass index (BMI) (OR: 1.07, 95%CI: 1.06-1.08, P < 0.001), waist circumference (WC) (OR: 1.03, 95%CI: 1.02-1.03 P < 0.001), lifestyle (OR: 0.45, 95%CI: 0.42-0.48, P < 0.001), and family history (OR: 4.28, 95%CI: 4.04-4.54, P < 0.001) were the most significant predictors of high-risk CRC. Healthy lifestyle was a protective factor, whereas family history was the most significant risk factor. The area under the curve was 0.734 (95%CI: 0.723-0.745) for the final validation set ROC curve and 0.735 (95%CI: 0.728-0.742) for the training set ROC curve. The calibration curve demonstrated a high correlation between the CRC high-risk population predicted by the nomogram model and the actual CRC high-risk population.CONCLUSION:The early-screening nomogram model for CRC prediction in high-risk populations developed in this study based on age, BMI, WC, lifestyle, and family history exhibited high accuracy.

Background:Randomized trials have shown a survival benefit for fruquintinib over placebo in patients with metastatic colorectal cancer (mCRC) that progressed after standard therapies, but real-world prognostic analyses have been seldom reported. We evaluated survival, safety outcomes, and predictive and prognostic factors in patients treated with fruquintinib in a real-life setting. Methods:We conducted a multi-center study by collecting relevant data on patients with advanced colorectal cancer (CRC) who received fruquintinib, focusing on progression-free survival (PFS), overall survival (OS), and L3 skeletal muscle index (SMI), including safety follow-up. Results:From January 2020 to January 2022, a total of 140 patients were selected and included in this study. The cut-off date was 30 July 2022. The median follow-up time was 18.3 months (range, 6-29.3 months) and the median age of included cases was 63 years (range, 32-81 years). The median PFS and OS for the 140 patients was 6.3 and 12.6 months, respectively. The median PFS and OS for the 76 patients who were included in SMI analysis was 6.0 and 12.0 months, respectively. Multivariate analysis suggested brain metastasis {hazard ratio (HR) [95% confidence interval (CI)]: 2.779 (1.162-6.646), P=0.02}, decrease in SMI of >5% [HR (95% CI): 9.732 (2.201-43.028), P=0.003], and baseline carcinoembryonic antigen (CEA) level [HR (95% CI): 4.061 (1.391-11.858), P=0.01] as independent predictors of OS. The most common treatment-related adverse events (TRAEs) were hypertension (24, 17.1%), fatigue (21, 15%), and hand-foot syndrome (20, 14.3%); 9 (13.6%) and 15 (10.7%) patients had dose reduction and treatment discontinuation due to TRAEs respectively. Conclusions:The real-world efficacy and safety of fruquintinib in advanced CRC patients are numerically superior to that in the previous phase III studies. SMI, brain metastasis and CEA could serve as potential markers for patient selection.

Background We aimed to estimate the global burden of colorectal cancer (CRC) between 1990 and 2019. Methods Data were extracted from the Global Burden of Disease study 2019. Estimated annual percentage changes (EAPCs) were calculated to quantify temporal trends in the age-standardized rates of CRC incidence, deaths, and disability-adjusted life-years (DALYs) by age, sex, region, and country. The correlations of EAPCs in the age-standardized rates with sociodemographic index (SDI) were also analyzed. Results From 1990 to 2019, the CRC incidence, deaths, and DALYs increased worldwide by 157%, 110%, and 96%, respectively. The global age-standardized incidence rate increased (EAPC, 0.58; 95% confidence interval [CI], 0.51–0.66), whereas both the age-standardized death rate (EAPC, −0.21; 95% CI, −0.28 to −0.14) and age-standardized DALY rate (EAPC, −0.21; 95% CI, −0.26 to −0.15) presented downward trends. As for regions, the largest increases in the age-standardized incidence rate, age-standardized death rate, and age-standardized DALY rate were observed in East Asia. In terms of countries, the largest increase in CRC incidence was found in Equatorial Guinea (3.98), followed by Vietnam (3.79) and China (3.66). The age-standardized incidence rate was higher in men than in women. Negative correlations were found between the EAPC in the age-standardized incidence rate of CRC and the SDI. Conclusions Future CRC preventive strategies should focus on the male population and older adults, especially in East Asia, Qatar, United Arab Emirates, Saudi Arabia, and other high-risk regions.

The researchers set the purpose of appraising how curcumin performs its protective function in colon cancer based on regulation of lncRNA NBR2 targeting Notch1 for epithelial-mesenchymal transition. Curcumin at 10-50 mu mol/L inhibited SW480 cell proliferation. With rising curcumin concentration, the protein expression of Vimentin significantly decreased, whereas E-cadherin presented an increased protein expression (P<0.05). Curcumin up-regulated NBR2 expression but down-regulated Notch1 expression dose-dependently. NBR2 and Notch1 expressions were negatively correlated with each other. The Notch1 expression in curcumin treatment groups was suppressed by NBR2 overexpression, but enhanced by NBR2+Notch1 treatment. The NBR2+Notch1 group exhibited a strengthen cell proliferation ability compared with the NBR2 group. In curcumin treatment groups, the roles of NBR2 overexpression in suppressing cell proliferation was weakened by overexpressed Notch1. LncRNA NBR2 is a vital player in regulating curcumin to exert its inhibitory effects on cell proliferation, probably by down-regulating the Notch1 pathway in the case of colon cancer.

Background:Chemotherapy was recommended as the 1st or 2nd line standard of care for patients with refractory or metastatic colorectal cancer (mCRC). Extra cautions are needed for elderly patients, because cytotoxic regimens may induce unexpected adverse effects due to their impaired physical condition and tolerability. Currently, there is no evidence for the treatment in elderly patients. This case reports a new ideas to the treatment of elderly mCRC patients.Case Description:An 82-year-old man was diagnosed with descending colon cancer and underwent radical operation revealed stage IIIB cancer (pT4aN1cM0) in June 2016, followed by adjuvant chemotherapy (6 cycles of XELOX). The disease relapsed in June 2018, and the patient was prescribed Tegafur for 6 months. In December 2018, he was admitted to hospital due to intestinal obstruction with performance status (PS) score of 3 and nutrition score (NRS2002) of 5. According to a multidisciplinary team (MDT) meeting: considering that the adverse effects of front-line treatment are dominated by myelosuppression, the general condition of the patient is currently poor. The patient received fruquintinib as the second-line treatment which was interrupted for one month due to grade 3 hypertension and proteinuria. The restarted dose was reduced from 5 to 3 mg/day and continued until the last follow-up. The disease did not progress during 25-months of Fruquintinib treatment. Unfortunately, the patient was bedridden for a long time after an accidental fall resulting in a pulmonary infection and finally died of respiratory failure in January 2021.Conclusions:CRC patients with advanced age and poor general condition require MDT meetings and individualized treatment. Despite of an advanced age, poor physical condition, and intense tumor burden, Fruquintinib as the second-line treatment achieved satisfactory disease control in this case. Adverse events could be relieved by dose reduction. Thus, fruquintinib could be a treatment option in refractory elderly CRC patients.

Left-sided colon cancer (LCC) and right-sided colon cancer (RCC) have distinct characteristics in tumor immune microenvironment (TIME). Although existing studies have shown a strong association between gene mutations and TIME, whether the regulatory mechanisms between gene mutations and TIME are different between RCC and LCC is still unclear. In this study, we showed the fractions of CD8+ T cells were higher while those of regulatory T cells were lower in RCC. Besides, a stronger association between gene mutations and TIME was observed in RCC. Specifically, using multi-omics data, we demonstrated the mutations of most top mutated genes (TMGs) including BRAF, PCLO, MUC16, LRP2, ANK3, KMT2D, RYR2 made great contributions to elevated fraction of immune cells by up-regulating immune-related genes directly or indirectly through miRNA and DNA methylation, whereas the effects of APC, TP53 and KRAS mutations on TIME were reversed in RCC. Remarkably, we found the expression levels of several immune checkpoint molecules such as PD-1 and LAG3 were correlated with corresponding DNA methylation levels, which were associated with the mutations of TMGs in RCC. In contrast, the associations between gene mutations and TIME were less significant in LCC. Besides, survival analyses showed APC mutation had adverse impact on immunotherapy while patients with BRAF mutation were more suitable for immunotherapy in colon cancer. We hope that our results will provide a deeper insight into the sophisticated mechanism underlying the regulation between mutations and TIME, and thus boost the discovery of differential immunotherapeutic strategies for RCC and LCC.

Background: Telomere is essential for chromosomal stability and its length has been proven to be related to prognosis in many malignant tumors. This study aims to investigate the relevance of telomere length with clinical and pathologic features and its prognostic value in colorectal cancer (CRC). Methods: Telomere status of CRC and adenoma cells were measured by telomere-specific quantitative fluorescent in situ hybridization (Q-FISH). The relative telomere length (RTL) was calculated as the mean telomere fluorescent intensity units (TFUs) in carcinoma cell divided by the TFU in cancer-associated fibroblast cell (CAF). Results: One hundred CRC patients, who were received surgery treatment during 2013 to 2014 and fifty-seven patients who underwent the examination of colonoscope and were confirmed as adenoma were enrolled. TFUs of carcinoma cell and CAF were statistically significantly lower than in adjacent mucosa cell (P=0.0079). Although there was no difference between the three kinds of adenoma cells (P=0.5457), TFU in adenoma cells was significantly lower than in CAF (P<0.0001) and independent with age. TFU and the RTL were statistically significantly lower in adenoma cells than in carcinoma (all P<0.0001). TFU of carcinoma cell in distant metastases patients were significantly lower than that without distant metastases patients (P=0.002). When cut by the median value of TFU of carcinoma cell and RTL, patients with a lower TFU or RTL had statistically significantly poorer overall survival (OS) (P=0.0027, HR: 4.6, 95% CI: 1.9-11.0; P=0.0163, HR: 2.95, 95% CI: 1.22-7.12) and disease-free survival (DFS) (P=0.0057, HR: 3.14, 95% CI: 1.40-7.06; P=0.0271, HR: 2.49, 95% CI: 1.11-5.59, respectively) than those patients with higher TFU or RTL. On multivariate analysis, the TFU of carcinoma cell was proved to be an independent prognostic value both for OS and DFS (P=0.0005, HR: 4.975, 95% CI: 1.616-15.385; P=0.007, HR: 3.57, 95% CI: 1.410-9.010). Conclusions: The length of telomere in carcinoma and adenoma cells were consistently shorter and the telomere changes were early carcinogenesis event, even the epithelial cells were morphologically not malignant. The length of telomere was associated with tumor metastases and prognosis, suggesting telomere probably was an important cue of the biological behavior of CRC.

Enhancer RNAs (eRNAs) are a subclass of long noncoding RNAs (lncRNAs) that have a wide effect in human tumors. However, the systematic analysis of potential functions of eRNAs-related genes (eRGs) in colon cancer (CC) remains unexplored. In this study, a total of 8231 eRGs including 6236 protein-coding genes and 1995 lncRNAs were identified in CC based on the multiple resources. These eRGs showed higher expression level and stability compared to other genes. What's more, the functions of these eRGs were closely related to cancer. Then a prognostic prediction model with 12 eRGs signatures were obtained for colon adenocarcinoma (COAD) patients. ROC curves showed the AUCs were 0.81, 0.77, and 0.78 for 1-, 3-, and 5-year survival prediction, respectively. And the prognostic model also manifested good performance in the validation datasets. Besides, the expression levels of two prognostic signatures, TMEM220 and LRRN2, were verified to be significantly lower in CC tissues than in adjacent noncancerous tissues (p < .05). Finally, the distinct molecular features were characterized between the high- and low-risk group through multiomics analysis including DNA mutation and methylation. Our results show eRGs signatures based prognostic model has high accuracy and may provide innovative biomarkers in COAD.

Background To understand the biological effect of gut microbiome on the progression of colorectal cancer (CRC), we sequenced the V3-V4 region of the 16S rRNA gene to illustrate the overall structure of microbiota in the CRC patients. Methods In this study, a total of 66 CRC patients were dichotomized into different groups based on the following characteristics: paired tumor and adjacent normal tissues, distal and proximal CRC segments, MMR (-) and MMR (+), different TNM staging and clinic tumor staging. Results By sequencing and comparing the microbial assemblages, our results indicated that 7 microbe genus (Fusobacterium, Faecalibacterium, Akkermansia, Ruminococcus2, Parabacteroides, Streptococcus, and f_Ruminococcaceae) were significantly different between tumor and adjacent normal tissues; and 5 microbe genus (Bacteroides, Fusobacterium, Faecalibacterium, Parabacteroides, and Ruminococcus2) were significantly different between distal and proximal CRC segments; only 2 microbe genus (f_Enterobacteriaceae and Granulicatella) were significantly different between MMR (-) and MMR (+); but there was no significant microbial difference were detected neither in the TNM staging nor in the clinic tumor staging. Conclusion All these findings implied a better understanding of the alteration in the gut microbiome, which may offer new insight into diagnosing and therapying for CRC patients.

Qin-Song Sheng 1 Kang-Xin He Jian-Jiong Li Zi-Feng Zhong Fei-Xia Wang Le-Lin Pan 1 Jian-Jiang Lin 1 1Department of Colorectal and Anal Surgery, the First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou, People’s Republic of China; 2State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, the First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou, People’s Republic of China; 3Department of Colorectal and Anal Surgery, the First Affiliated Hospital of College of Medicine, Zhejiang University, Ningbo, People’s Republic of China Background: To understand the biological effect of gut microbiome on the progression of colorectal cancer (CRC), we sequenced the V3-V4 region of the 16S rRNA gene to illustrate the overall structure of microbiota in the CRC patients. Methods: In this study, a total of 66 CRC patients were dichotomized into different groups based on the following characteristics: paired tumor and adjacent normal tissues, distal and proximal CRC segments, MMR (-) and MMR (+), different TNM staging and clinic tumor staging. Results: By sequencing and comparing the microbial assemblages, our results indicated that 7 microbe genus (Fusobacterium, Faecalibacterium, Akkermansia, Ruminococcus2, Parabacteroides, Streptococcus, and f_Ruminococcaceae) were significantly different between tumor and adjacent normal tissues; and 5 microbe genus (Bacteroides, Fusobacterium, Faecalibacterium, Parabacteroides, and Ruminococcus2) were significantly different between distal and proximal CRC segments; only 2 microbe genus (f_Enterobacteriaceae and Granulicatella) were significantly different between MMR (-) and MMR (+); but there was no significant microbial difference were detected neither in the TNM staging nor in the clinic tumor staging. Conclusion: All these findings implied a better understanding of the alteration in the gut microbiome, which may offer new insight into diagnosing and therapying for CRC patients.

目的 评价术前经肠镜浆膜下自体血标记定位法在腹腔镜结直肠手术中的应用效果.方法 对60例需行腹腔镜结直肠癌根治术的患者进行前瞻性研究.术前1 d行肠镜检查,在肿瘤下缘0.5 cm处行浆膜下四点法自体血标记肿瘤定位,术中观察寻找标记位置,术后剖视标本确认定位是否准确,对操作时间、操作成功率以及有无并发症进行评估,术后病理评估切除标本的切缘情况.结果 成功在58例患者中确定了自体血标记部位,顺利完成了腹腔镜结直肠癌根治术,成功率96.7％,所有患者均无出血、穿孔和发热等并发症;2例未找到标记点,行术中肠镜定位后成功手术.手术过程均顺利.术后剖视标本,60例患者均显示定位准确,其中2例患者肿瘤位于脾曲,标记在背侧显示,腹侧无标记,导致术中无法辨认,标本病理回报显示切缘均阴性.结论 经肠镜浆膜下自体血标记为腹腔镜结直肠手术前定位提供了一种安全简便、经济有效的方法,可以成为新的替代方法.

目的 评价肠镜下切开引流术治疗直肠黏膜下脓肿的临床疗效和安全性.方法 回顾性分析2013年1月-2018年12月在中国科学院大学宁波华美医院行肠镜下直肠黏膜下脓肿切开引流术的70例患者的临床资料,分析治疗及并发症发生情况.结果 均成功行肠镜下脓肿切开引流术,平均操作时间(15.0±5.2)min.24例患者脓腔巨大置入引流管,46例患者脓腔较小置入引流条,3 d后拔除引流管及引流条.所有患者均治愈出院,无明显并发症发生,无1例死亡.术后随访12个月,16例患者形成肛瘘,来院行肛瘘手术后治愈,54例患者未再复发.结论 在有经验的内镜中心,对于直肠黏膜下脓肿患者行肠镜下切开引流术是一种安全、有效的微创治疗方法.

目的 探讨降钙素原(PCT)和辅助性T细胞(Th) Th1/Th2比值对结直肠癌患者术后发生感染性并发症的诊断价值.方法 选取2015年1月-2017年12月医院收治的95例结直肠癌术后合并感染性并发症患者为感染组,95例术后未发生感染性并发症的结直肠癌患者为对照组.收集两组患者术前1d、术后3d、7d晨起空腹外周血,采用全自动血液细胞分析仪检测白细胞(WBC)计数,采用酶联免疫吸附测定(ELISA)试验检测血清PCT水平,采用流式细胞术检测外周血Th1、Th2细胞含量及Th1/Th2比值,应用受试者工作特征(ROC)曲线分析WBC、PCT和Th1/Th2比值对结直肠癌患者术后发生感染性并发症的诊断价值.结果 术后3d、7d,感染组患者血清PCT水平、外周血Th2细胞含量、WBC计数均高于对照组,Th1/Th2比值低于对照组(P＜0.05);ROC曲线显示,术后3d、7d,PCT、Th1/Th2比值诊断结直肠癌患者术后发生感染性并发症的AUC均＞0.80.PCT联合Th1/Th2比值诊断结直肠癌患者术后发生感染性并发症的敏感性和特异性与指标单独诊断相近.结论 PCT和Th1/Th2比值是早期诊断结直肠癌患者术后发生感染性并发症的快速、可靠指标.

目的 分析肛周脓肿术后引起切口感染的影响因素,为控制切口感染及治疗提供临床参考意见.方法 选取2014年1月-2016年12月医院收治的107例肛周脓肿切排术患者作为研究对象,回顾性分析患者的临床病例资料.对感染部位标本的培养和鉴定,研究切口感染的病原学特点,运用单因素以及多因素Logistics回归分析探讨其感染的影响因素.结果 病原学培养结果显示革兰阴性菌30株,占76.92％,革兰阳性菌9株,占23.07％;单因素分析结果表明,深部脓肿、有肛周皮肤感染灶、住院时间长的患者更易发生切口感染,差异具有统计学意义(P＜0.05).结论 导致患者切口感染的主要病原菌为革兰阴性菌.感染与深部脓肿、有肛周皮肤感染灶以及住院时间长相关,临床上应针对上述因素采取相应预防措施.